Mitochondrial-Derived Peptides Compared: Humanin vs MOTS-c vs SS-31 in Aging and Cytoprotection Research

Introduction: The Mitochondria as a Signaling Organelle

Researchers can use our peptide comparison page to evaluate pricing and sourcing options.

Mitochondria were long viewed as simple powerhouses — organelles tasked solely with generating ATP. That paradigm has shifted dramatically. Researchers now understand that mitochondria function as sophisticated signaling hubs, producing bioactive peptides encoded by their own genome or specifically designed to target their inner architecture (Miller et al., 2020).

Three peptides stand at the center of this mitochondrial signaling revolution: Humanin , a 24-amino-acid cytoprotective peptide discovered in 2001; MOTS-c, a 16-amino-acid metabolic regulator identified in 2015; and SS-31 (Elamipretide), a synthetic mitochondria-targeting tetrapeptide designed to restore organelle function. While each operates through distinct molecular mechanisms, all three converge on mitochondrial integrity, cellular stress resistance, and aging biology.

This comparison examines how these peptides differ in origin, structure, mechanism, and research utility — providing laboratory investigators with the context needed to select appropriate compounds for their experimental systems.

---

Genomic Origins and Discovery

Humanin: The First Mitochondrial-Derived Peptide

Humanin (HN) was identified in 2001 by Hashimoto and colleagues through functional expression screening of cDNA libraries from the occipital cortex of Alzheimer's disease brains. They discovered a short polypeptide that abolished neuronal cell death caused by multiple familial AD genes and amyloid-beta (Aβ) peptides ([Hashimoto et al., 2001]()). The 24-amino-acid peptide (sequence: MAPRGFSCLLLLTSEIDLPVKRRA) is encoded by a small open reading frame (sORF) within the MT-RNR2 gene — the mitochondrial 16S ribosomal RNA region.

This discovery was groundbreaking for two reasons: it established that the mitochondrial genome contains functional peptide-coding sequences beyond the canonical 13 oxidative phosphorylation (OXPHOS) subunits, and it demonstrated that mitochondria can directly influence cell survival signaling.

MOTS-c: The Exercise-Mimetic from 12S rRNA

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) was discovered in 2015 by Changhan Lee and colleagues at the University of Southern California. This 16-amino-acid peptide (sequence: MRWQEMGYIFYPRKLR) is encoded by a sORF within the MT-RNR1 gene — the mitochondrial 12S rRNA region (Lee et al., 2015). Unlike Humanin, which was found through neuroprotection screening, MOTS-c was identified through systematic bioinformatic analysis of potential mitochondrial sORFs, then validated functionally.

MOTS-c is notable for its role as a mitochondrial-encoded signal that targets the nuclear genome — a form of retrograde signaling from mitochondria to nucleus that was largely theoretical before its discovery.

SS-31: A Synthetic Mitochondria-Targeting Peptide

SS-31 (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH₂), also known as Elamipretide or MTP-131, stands apart from Humanin and MOTS-c in a fundamental way: it is not mitochondrial-derived. SS-31 is a synthetic tetrapeptide designed by Hazel Szeto and Peter Schiller, engineered to selectively accumulate within mitochondria due to its alternating aromatic-cationic motif. While it is not encoded by mtDNA, its primary pharmacological target is the inner mitochondrial membrane, making it a functional peer of the endogenous MDPs in research applications (Chavez et al., 2020).

---

Structural Characteristics

All three are relatively small peptides, but they span a significant range — from SS-31's compact four residues to Humanin's 24. This size difference has important implications for stability, membrane permeability, and pharmacokinetics in research settings.

---

Mechanisms of Action

Humanin: Multi-Receptor Cytoprotection

Humanin operates through at least three characterized mechanisms:

1. FPRL-1/FPRL-2 Receptor Signaling: Humanin binds formyl peptide receptor-like 1 and 2 (FPRL-1/FPRL-2), activating downstream ERK1/2 and STAT3 pathways that promote cell survival. This extracellular signaling mode positions Humanin as both an autocrine and paracrine factor (Miller et al., 2022).

2. BAX Interaction: Humanin directly interacts with the pro-apoptotic BCL-2 family member BAX, preventing BAX translocation to mitochondria and subsequent cytochrome c release. This anti-apoptotic mechanism is central to Humanin's cytoprotective function across multiple cell types (Bhatt et al., 2021).

3. IGFBP-3 Modulation: Humanin binds insulin-like growth factor binding protein 3 (IGFBP-3), interfering with IGFBP-3-mediated apoptosis and modulating IGF-I signaling cascades.

Collectively, these mechanisms give Humanin a uniquely broad cytoprotective profile — it can suppress cell death through both intracellular (BAX) and extracellular (receptor-mediated) pathways.

MOTS-c: AMPK-Mediated Metabolic Regulation

MOTS-c's mechanism centers on metabolic signaling rather than direct cytoprotection:

1. AMPK Activation: MOTS-c activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. This activation appears to occur through modulation of the folate cycle and de novo purine biosynthesis, leading to accumulation of the AMPK-activating metabolite AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) (Lee et al., 2015).

2. Nuclear Translocation Under Stress: Under metabolic or oxidative stress, MOTS-c translocates from the cytoplasm to the nucleus, where it interacts with stress-responsive transcription factors to regulate adaptive gene expression. This retrograde mito-nuclear signaling is one of the most distinctive features of MOTS-c biology (Mohtashami et al., 2022).

3. Folate-Methionine Cycle Regulation: MOTS-c influences one-carbon metabolism by modulating the folate cycle, with downstream effects on purine synthesis, methionine metabolism, and cellular methylation patterns.

MOTS-c has been described as an "exercise mimetic" because its metabolic effects — AMPK activation, enhanced glucose utilization, and fatty acid oxidation — parallel many of the molecular responses to physical exercise.

SS-31: Cardiolipin-Targeted Bioenergetic Restoration

SS-31's mechanism is the most structurally direct of the three:

1. Cardiolipin Binding: SS-31 selectively interacts with cardiolipin (CL), a phospholipid unique to the inner mitochondrial membrane (IMM). This interaction stabilizes the cristae architecture that houses the electron transport chain (ETC) complexes (Birk et al., 2013).

2. Electron Transport Optimization: By maintaining proper CL-protein interactions, SS-31 preserves the structural organization of ETC supercomplexes (respirasomes), optimizing electron flow and reducing electron leak that generates reactive oxygen species (ROS) (Chavez et al., 2020).

3. Cytochrome c Function: SS-31 modulates the interaction between CL and cytochrome c, enhancing cytochrome c's electron carrier function while reducing its peroxidase activity — an activity associated with pro-apoptotic signaling and CL oxidation.

Unlike Humanin and MOTS-c, which act primarily through signaling pathways, SS-31 works by physically maintaining the structural integrity of the mitochondrial machinery.

---

Research Applications and Experimental Models

Humanin in Neuroscience and Aging Research

Humanin research has concentrated on two primary areas:

Neurodegenerative Disease Models: Humanin and its potent analog [Gly14]-Humanin (HNG) have demonstrated neuroprotective effects in cellular and animal models of Alzheimer's disease, including protection against Aβ-induced toxicity, tau hyperphosphorylation models, and oxidative stress paradigms. HNG, which contains a glycine substitution at position 14, exhibits approximately 1,000-fold greater potency than wild-type Humanin in standard cytoprotection assays.

Aging and Longevity: Circulating Humanin levels decline with age in both research animal models and observational studies of centenarian cohorts. Transgenic overexpression of Humanin in C. elegans and rodent models has been linked to extended lifespan and improved age-related functional parameters (Mehta et al., 2020).

Cardiac Research: Humanin has shown cardioprotective properties in ischemia-reperfusion models, where it reduces mitochondrial dysfunction through complex I activity modulation and ROS attenuation ([Thummasorn et al., 2018]()).

MOTS-c in Metabolic and Exercise Biology

MOTS-c research has focused on metabolic regulation:

Obesity and Insulin Resistance Models: In diet-induced obesity models, MOTS-c administration has been associated with improved insulin sensitivity, reduced fat mass, and enhanced glucose homeostasis. These effects are primarily mediated through AMPK-dependent pathways.

Exercise Physiology: MOTS-c levels increase with physical exercise, and its molecular effects recapitulate many exercise-induced adaptations. This has made it a subject of intense interest in exercise biology research, particularly regarding the molecular mechanisms by which physical activity confers systemic metabolic benefits.

Cellular Senescence: Recent research has explored MOTS-c's role in modulating cellular senescence pathways, including its effects on pancreatic islet cell senescence in diabetes-related models.

SS-31 in Mitochondrial Disease and Organ Protection

SS-31 has the broadest pre-clinical research application profile:

Cardiac Models: SS-31 has been extensively investigated in cardiac ischemia-reperfusion injury models, heart failure models, and age-related cardiac decline. Late-life administration in aged animal models has been associated with reversal of cardiac diastolic dysfunction and restoration of mitochondrial structure.

Renal Models: SS-31 has shown renoprotective effects in models of acute kidney injury, diabetic nephropathy, and unilateral ureteral obstruction, primarily through preservation of mitochondrial structure and reduction of oxidative damage (Application review, 2024).

Barth Syndrome: SS-31 (elamipretide) has been investigated in models of Barth syndrome, a rare genetic disorder caused by mutations in the tafazzin gene that impair cardiolipin remodeling — making it a logical therapeutic target for a CL-binding peptide.

Skeletal Muscle Aging: Age-related mitochondrial dysfunction in skeletal muscle, including reduced exercise capacity and increased oxidative stress, has been a key application area for SS-31 research.

---

The Broader MDP Family: SHLPs and Beyond

Humanin and MOTS-c are part of a larger family of mitochondrial-derived peptides (MDPs). Following the discovery of Humanin, bioinformatic searches of the MT-RNR2 region identified six additional peptides encoded by sORFs — the small humanin-like peptides SHLP1 through SHLP6, ranging from 20 to 38 amino acids in length (Cobb et al., 2016).

Among the SHLPs, SHLP2 and SHLP3 have shown cytoprotective and anti-apoptotic effects similar to (though weaker than) Humanin, while SHLP6 exhibits a paradoxically pro-apoptotic function. SHLP2 has attracted particular interest for its effects on energy homeostasis and its potential relevance to age-related macular degeneration research.

The discovery of SHLPs suggests that the mitochondrial genome may contain additional undiscovered bioactive peptides — a prospect supported by the identification of novel mitochondrial microproteins through ribosome profiling and proteomics techniques.

---

Head-to-Head Comparison: Key Differentiators

Mechanism Overlap and Divergence

While all three peptides ultimately support mitochondrial function and cellular resilience, their approaches differ fundamentally:

• •Humanin acts as an endocrine/paracrine cytoprotective signal — it protects cells from death through receptor-mediated and direct anti-apoptotic mechanisms, essentially functioning as a survival signal.

• •MOTS-c acts as a metabolic regulator — it improves cellular energy management through AMPK activation and nuclear gene regulation, functioning more like a metabolic hormone.

• •SS-31 acts as a structural pharmacological agent — it physically maintains the integrity of the inner mitochondrial membrane and electron transport chain, functioning as a molecular scaffold for bioenergetic machinery.

Research Context Selection

For investigators choosing between these peptides:

Choose Humanin when: The research question involves cytoprotection, anti-apoptosis, neuroprotection, or cell survival signaling. Humanin is most relevant for neurodegenerative disease models, ischemia-reperfusion injury, and aging-related cell death paradigms.

Choose MOTS-c when: The research question involves metabolic regulation, insulin sensitivity, exercise biology, or AMPK-mediated pathways. MOTS-c is most relevant for obesity models, diabetes research, and exercise mimetic studies.

Choose SS-31 when: The research question involves mitochondrial bioenergetics, electron transport chain dysfunction, cardiolipin biology, or organ-specific ischemia-reperfusion injury. SS-31 is most relevant for cardiac research, renal injury models, and disorders of mitochondrial structure.

Stability and Handling Considerations

In laboratory settings, handling requirements differ:

• •Humanin is a 24-mer peptide with moderate stability in aqueous solution. It is typically reconstituted in sterile water or PBS at concentrations of 1 mg/mL and stored at -20°C. The S14G analog (HNG) is preferred for many applications due to its enhanced potency.

• •MOTS-c is a 16-mer peptide that is generally stable when lyophilized and stored at -20°C. Reconstitution in sterile water is standard. Working solutions should be prepared fresh due to potential adsorption to plastic surfaces.

• •SS-31 contains a D-arginine residue and an amidated C-terminus, conferring greater proteolytic stability than the endogenous MDPs. It is typically reconstituted in sterile water or saline and is more resistant to degradation in cell culture media than Humanin or MOTS-c.

---

Current Research Frontiers

Combination Studies Researchers planning multi-peptide protocols can use our [peptide stack builder](/tools/stack-builder) to map combination strategies.

An emerging area of research explores whether combinations of mitochondrial peptides produce synergistic or additive effects. Since Humanin, MOTS-c, and SS-31 operate through largely independent mechanisms — cytoprotective signaling, metabolic regulation, and structural maintenance, respectively — they represent complementary rather than redundant interventions in experimental systems.

Genetic Variants and Population Differences

A notable feature of mtDNA-encoded peptides is that their sequences can vary between individuals based on mitochondrial haplogroup. A well-characterized example is the m.1382A>C polymorphism in the MOTS-c gene, more prevalent in East Asian populations, which alters the peptide sequence and has been associated with differences in metabolic parameters. These genetic variants introduce important considerations for research reproducibility across different cell line backgrounds.

Analytical Detection Methods

Quantifying endogenous MDP levels remains technically challenging. Humanin and MOTS-c are present at picomolar to low nanomolar concentrations in circulation, requiring sensitive immunoassay or mass spectrometry-based detection methods. Standardization of measurement techniques is an active area of methodology development.

---

Summary

Humanin, MOTS-c, and SS-31 represent three distinct strategies for maintaining mitochondrial function and cellular resilience:

• •Humanin — an endogenous cytoprotective signal from the 16S rRNA gene, operating through multi-receptor anti-apoptotic pathways
• •MOTS-c — an endogenous metabolic regulator from the 12S rRNA gene, functioning through AMPK activation and nuclear translocation
• •SS-31 — a synthetic cardiolipin-targeting tetrapeptide, maintaining inner mitochondrial membrane structure and electron transport efficiency

Together, they illustrate the remarkable complexity of mitochondrial signaling and the organelle's role far beyond energy production. For research purposes, understanding their mechanistic differences enables more precise experimental design and more meaningful interpretation of results in the growing field of mitochondrial biology.

---

References

• •PMID: 41543486
• •PMID: 40574402
• •PMID: 42708867

2. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. PubMed

3. Chavez JD, et al. Mitochondrial protein interaction landscape of SS-31. PNAS. 2020;117(26):15363-15373. PubMed

4. Miller B, et al. Peptides derived from small mitochondrial open reading frames: Genomic, biological, and therapeutic implications. Exp Cell Res. 2020;393(2):112056. PubMed

5. Miller B, et al. Mitochondria-derived peptides in aging and healthspan. J Clin Invest. 2022;132(9):e158449. PubMed

6. Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261. PubMed

7. Cobb LJ, et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY). 2016;8(4):796-809. PubMed

8. Mohtashami Z, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022;23(19):11991. PubMed

9. Mehta HH, et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020;12(12):11185-11199. PubMed

11. Bhatt A, et al. Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases. Life Sci. 2021;264:118679. PubMed

12. Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction. Mitochondrion. 2024;75:101846. PubMed

*Note: All compounds discussed are for research use only (

References

• •PMID: 42262906
• •
• •PMID: 42633878

RUO). These peptides are research chemicals intended for in vitro and laboratory investigation. Not for human or veterinary use.*

---

Research Suppliers: Where to Source These Mitochondrial Peptides (2026)

The following pricing for Humanin, MOTS-c, and SS-31 (elamipretide) is sourced from the Peptides.SO live listings database (September 2026). All listings are verified in-stock.

Humanin (10 mg vials)

> Compare Humanin offers → peptides.so/peptide/humanin

MOTS-c (per mg)

> Compare MOTS-c offers → peptides.so/peptide/mots-c

SS-31 / Elamipretide (per mg, September 2026)

SS-31 (Elamipretide) has 55 active research listings across the Peptides.SO supplier network — a smaller but growing market compared to the MDPs. Pricing reflects the specialized synthesis required for this d-amino acid-containing tetrapeptide.

SS-31 market range: $0.06–$1,092/mg across 55 active listings. Standard research-grade listings (5–10mg, ≥98% HPLC) fall in the $2.81–$5.03/mg range. Confirm d-Arg incorporation and amidated C-terminus via mass spectrometry before use.

> Compare SS-31 / Elamipretide offers → peptides.so/peptide/ss-31

All peptides are for research use only (RUO). Not for human or veterinary use.

---

Frequently Asked Questions: Mitochondrial Peptides Compared

Q: Why are these three peptides — Humanin, MOTS-c, and SS-31 — considered a mechanistically distinct class?

Humanin and MOTS-c are genuinely mitochondria-encoded (translated from ORFs within the mitochondrial genome), making them unique endogenous peptides that evolved within the organelle rather than the nuclear genome. SS-31 is a synthetic tetrapeptide designed to target cardiolipin on the inner mitochondrial membrane. They are grouped conceptually because all three measurably modulate mitochondrial function in research models, but their origins, targets, and downstream pathways are distinct.

Q: Which of these three peptides shows the strongest evidence for nuclear translocation and gene expression changes?

MOTS-c has the best-characterized nuclear signaling: under metabolic stress, cytoplasmic MOTS-c translocates to the nucleus and binds to ARE/ATF response elements, modulating transcription of antioxidant and metabolic genes. Humanin's signaling is predominantly receptor-mediated at the cell surface (CNTFR/IL-6ST/WSX-1 trimeric receptor) with downstream JAK-STAT activation. SS-31 acts locally at the inner mitochondrial membrane without documented nuclear translocation.

Q: How do the tissue distributions of Humanin and MOTS-c compare in aging studies?

Circulating Humanin declines with age in human plasma (notably in individuals with Alzheimer's disease risk and in elderly cohorts), with the highest expression in tissues facing high oxidative burden (testis, liver, brain). MOTS-c circulates acutely in response to exercise and declines with age and metabolic disease. Both show tissue-specific variation: MOTS-c is particularly relevant to skeletal muscle and liver metabolic biology, while Humanin has a broader cytoprotective distribution including neurons and retinal cells.

Q: What is the most important structural difference between SS-31 and the natural MDPs?

SS-31 (D-Arg-2'6'-dimethylTyr-Lys-Phe-NH2) incorporates non-natural amino acids (dimethylated tyrosine) and an amidated C-terminus to improve stability and membrane penetration. Being a synthetic tetrapeptide, it has no endogenous receptor — it acts by direct cardiolipin binding. Humanin and MOTS-c are natural sequences with endogenous receptors and established signaling cascades, which makes their pharmacology more complex but also more physiologically interpretable in intervention studies.

Q: When would a researcher choose Humanin over MOTS-c for an in vitro experiment?

Humanin is preferred when the research focus is on apoptosis suppression (Bax-pathway antagonism), neuroprotection against amyloid-β or oxidative insults, or testicular/germ cell survival signaling. MOTS-c is preferred for studies examining insulin signaling, AMPK activation, folate-methionine cycle modulation, or exercise mimicry. For pure mitochondrial bioenergetic readouts (oxygen consumption, ATP production, cristae integrity), SS-31 often shows the most direct and consistent effects across cell types.

Q: Is there evidence for synergy between these peptides in combined treatment experiments?

Published data on combination treatments is limited but conceptually plausible given non-overlapping mechanisms: SS-31 could restore mitochondrial architecture and electron transport efficiency while MOTS-c activates downstream AMPK metabolic adaptation and Humanin suppresses stress-induced apoptosis. Any combination study would need to carefully control for additive versus synergistic effects and establish dose-response matrices individually before combining treatments. This remains an active area of mitochondrial research with limited peer-reviewed data as of 2026.

---

Further Reading:

• •Nootropic Peptides Compared: Semax vs Selank vs Dihexa vs P21 in Cognitive Research
• •Best Peptides for Anti-Aging Research: Science-Backed Compounds (2026)
• •Humanin: The Mitochondrial-Derived Peptide Redefining Cytoprotection Research
• •GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin — A Complete Research Guide (2026)
• •Reconstitution Calculator
• •Peptide Stack Builder